ライフサイエンスコーパス: placebo

1 placebo; P = 0.04 for 25-mg brensocatib vs. placebo).

2 validated 5D-Itch questionnaire (P = .002 vs placebo).

3 .67]; p=0.80 for 300 mg S44819 compared with placebo).

4 n), and control (standard hypocaloric diet + placebo).

5 assigned dulaglutide and 4372 were assigned placebo.

6 ble-blind injection of .08 mg/kg morphine or placebo.

7 rther randomly assigned to either vaccine or placebo.

8 the D2 receptor antagonist haloperidol, and placebo.

9 sulin use was lower with golimumab than with placebo.

10 spital cardiac arrest patients compared with placebo.

11 iated with higher rates of side-effects than placebo.

12 taneous injections of evolocumab (420 mg) or placebo.

13 s of either novel OPV2-c1, novel OPV2-c2, or placebo.

14 g; n = 9 each dose) and 12 patients received placebo.

15 in and 661 deaths in communities assigned to placebo.

16 atio to receive either LY-CoV555 or matching placebo.

17 s with apixaban and VKA and with aspirin and placebo.

18 o 14 days of once-daily nebulized AZD9412 or placebo.

19 andomly assigned to receive sotagliflozin or placebo.

20 ith elagolix plus add-back therapy than with placebo.

21 mL [95% CI, 26-598]; P=0.026) compared with placebo.

22 ved aspirin and 36 participants who received placebo.

23 00 mg of albendazole combination therapy; or placebo.

24 Safety and tolerability were similar to placebo.

25 VO2 peak with lumbar intrathecal fentanyl or placebo.

26 domized to the PCSK9 inhibitor alirocumab or placebo.

27 received simple bupivacaine and 52 received placebo.

28 mg modified-release twice daily or matching placebo.

29 s were randomized to 1200 mg daily of ALA or placebo.

30 cated to receive vitamin K and 79 to receive placebo.

31 ived SNF472 and 5 patients (6%) who received placebo.

32 e plasma insulin concentration compared with placebo.

33 g brensocatib doses, respectively, than with placebo.

34 ttack rate for lanadelumab was compared with placebo.

35 essant medication (sertraline) compared with placebo.

36 Random allocation to LD-MTX (<=20 mg/wk) or placebo.

37 k interval, and every 8 weeks thereafter) or placebo.

38 ed to receive allopurinol and 263 to receive placebo.

39 re during the 3-day course of amoxicillin or placebo.

40 re reported (rhinitis [JNJ-8678]; pneumonia [placebo]).

41 [95% CI -0.4 to 0.5; p=0.99]; fluoxetine vs placebo -0.1% [-0.5 to 0.3; p=0.86]; riluzole vs placebo

42 ebo -0.1% [-0.5 to 0.3; p=0.86]; riluzole vs placebo -0.1% [-0.6 to 0.3; p=0.77]).

43 treatment and placebo in PBVC (amiloride vs placebo, 0.0% [95% CI -0.4 to 0.5; p=0.99]; fluoxetine v

44 al benefit from targeted therapy (HR [versus placebo] 0.49, 95% CI 0.35-0.68, p<0.0001).

45 ed benefit with targeted therapy (HR [versus placebo] 0.75, 95% CI 0.44-1.26, p=0.27), especially if

46 of treatment [EOT] in MADRS-6 and -10 versus placebo: -1.5, P = 0.018; -1.9, P = 0.026, respectively)

47 ; ixekizumab Q2W: 32 [31%] of 102, p=0.0037; placebo: 14 [13%] of 105).

48 regimen was higher with finerenone than with placebo (2.3% and 0.9%, respectively).

49 ; ixekizumab Q2W: 41 [40%] of 102, p=0.0016; placebo: 20 [19%] of 105) and ASAS40 at week 52 (ixekizu

50 = 523; 17% [300 mg] and 6% [150 mg] vs 10% [placebo]; 24% [150 mg] vs 28% [placebo]) and 1 trial of

51 Patients (n=448) were randomized 1:1:1 to placebo, 25 mg of OM BID, or to pharmacokinetically guid

52 th 18 vs baseline was higher in Cit-B12 than placebo (33% vs 15%, p = 0.04).

53 domized 1:1 to receive 25 mg clazakizumab or placebo (4-weekly subcutaneous injections) for 12 weeks

54 ntly improved with ramucirumab compared with placebo (4.1 months [95% CI 3.3-4.8] vs 2.8 months [2.6-

55 se events were similar in TAK-003 (4.0%) and placebo (4.8%) recipients, and were consistent with expe

56 ouble-blind clinical trial with four groups: placebo, 5 mg/d, 10 mg/d, and 20 mg/d of oral tropisetro

57 ents, with rates per 100 person-years in the placebo, 50 mg, 150 mg, and 300 mg canakinumab groups of

58 on and received evolocumab (104 patients) or placebo (53 patients).

59 mized 2:1 to receive two doses of TAK-003 or placebo 90 days apart.

60 e more common with zoledronic acid than with placebo (96% vs 83%, respectively) and consisted mainly

61 acid and zinc supplementation compared with placebo (abdominal discomfort or pain: 66 [6%] vs 40 [3%

62 arousal threshold received 10 mg zolpidem or placebo according to a double-blind, randomised, cross-o

63 received 5 days of AVL-3288 (10, 30 mg) and placebo across three separate treatment weeks.

64 41.4 m (95% CI, 8.2-74.5), respectively; the placebo-adjusted least-squares between-group difference

65 ilure (31.7% with intervention vs 27.3% with placebo; adjusted risk difference, 0.03; 95% CI, -0.1 to

66 etween cardiac output and BP responses after placebo administration (r = 0.53, P = 0.0121), but this

67 00 healthy adults to receive morphine versus placebo after two nights of undisturbed sleep (US) and t

68 incidence of cardiovascular events than did placebo among participants without cardiovascular diseas

69 hibitor, and narrowband-ultraviolet B versus placebo and narrowband-ultraviolet B in patients with no

70 .31]; p=0.80 for 150 mg S44819 compared with placebo and OR 1.17 [95% CI 0.81-1.67]; p=0.80 for 300 m

71 In the placebo and praliciguat groups, changes in 6-minute walk

72 dala reactivity to fearful faces relative to placebo and similarly to lorazepam and also reduced conn

73 icacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Pso

74 nts, bezafibrate reduced morning (P = .01 vs placebo) and evening (P = .007) intensity of pruritus (V

75 chieved by means of an identical intravenous placebo, and blinding for vemurafenib was achieved by me

76 kg/min, P < 0.05) than in subjects receiving placebo, and it was associated with a significant increa

77 22 healthy controls (HCs) at baseline, post-placebo, and post-ketamine.

78 0 mg] vs 10% [placebo]; 24% [150 mg] vs 28% [placebo]) and 1 trial of nicotine replacement therapy at

79 r the oseltamivir arm and 84.0 hours for the placebo arm (P =; .34) in those with confirmed influenza

80 32.5 days (interquartile range 13-50) in the placebo arm and 34 days (interquartile range 17-62) in t

81 igher frequency of syncope (9.2%) in the OH+ placebo arm.

82 trolled trials comparing rivastigmine versus placebo at week 24 (n = 501) and rivastigmine patch vers

83 adjunctive BUP/SAM 2 mg/2 mg was superior to placebo (average difference change from baseline to week

84 yptoxanthin), HP-diet (hypocaloric HP-diet + placebo), beta-cryptoxanthin (standard hypocaloric diet

85 e randomized to either cocoa beverage versus placebo beverage.

86 C/CBD-equivalent cannabis, and 19.37 cm with placebo cannabis.

87 8.0) to weekly healthy lean donor FMT versus placebo capsules for 6 weeks.

88 Compared with placebo, CBD was associated with an increased likelihood

89 tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66;

90 d efficacy and safety of atezolizumab versus placebo combined with nab-paclitaxel followed by doxorub

91 the azithromycin communities, but not in the placebo communities.

92 This study evaluated the efficacy of the Placebo-Control Reminder Script (PCRS), a brief interact

93 However, a recent placebo-controlled clinical trial of AV-101 in depressio

94 -19) is currently being tested in randomized placebo-controlled clinical trials.

95 n and placebo in a randomized, double-blind, placebo-controlled crossover study.

96 Skin tests (STs) and single-blind placebo-controlled drug provocation tests (SBPCDPTs) wer

97 In this double-blind, placebo-controlled experimental medicine study, healthy

98 f the Women's Health Initiative, randomized, placebo-controlled hormone therapy trials of conjugated

99 to asthmatics in a randomized, double-blind placebo-controlled investigation.

100 We conducted a double-blind, randomized, placebo-controlled noninferiority trial involving childr

101 r outcome trials, most designed primarily as placebo-controlled noninferiority trials, but with many

102 cute Coronary Syndromes) was a double-blind, placebo-controlled randomized trial conducted from 2008

103 this multicentre, double-blind, randomised, placebo-controlled study done in 48 acute care hospitals

104 e-center, phase 2, randomized, double-blind, placebo-controlled study investigated the safety, tolera

105 This phase 3, double-blind, placebo-controlled study was done at 118 sites in 13 cou

106 In this double-blind, placebo-controlled study, we investigated whether a sing

107 1313/I1314L was evaluated in a double-blind, placebo-controlled trial (vaccine-placebo ratio, 2:1) at

108 A phase 1-2 randomized double-blind placebo-controlled trial enrolled 252 participants (210

109 We conducted a 24-wk randomized placebo-controlled trial in 126 overweight, non-insulin

110 ducted a multicenter, two-group, randomized, placebo-controlled trial in nine hospitals in Kenya and

111 This was a randomized, double-blind, placebo-controlled trial in which patients with severe a

112 This randomized, double-blind, placebo-controlled trial included patients with type 2 d

113 SHIFT was a randomized placebo-controlled trial investigating the effect of iva

114 FOURIER was a randomized, double-blind, placebo-controlled trial involving patients with atheros

115 We conducted a randomized double-blinded placebo-controlled trial to determine the effect of uste

116 A factorial, randomized, double-blind, placebo-controlled trial was conducted in infertility cl

117 In part 1 of this phase 2, randomized, placebo-controlled trial we sequentially enrolled 1.5-45

118 an international, randomised, double-blind, placebo-controlled trial.

119 5/23 received leronlimab after blinded placebo-controlled trials of remdesivir, sarilumab, seli

120 We conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 pat

121 To fill this gap, we conducted a randomized, placebo-controlled, double-blind pharmacological study t

122 This was a phase II placebo-controlled, double-blind, parallel-group, enrich

123 eceived the NMDAR antagonist S-ketamine in a placebo-controlled, double-blind, within-subject fashion

124 This randomised, double-blind, phase 3, placebo-controlled, multicentre trial compared once-dail

125 lity and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose-escalation stu

126 his international, double-blind, randomised, placebo-controlled, phase 3 study (D-CARE), patients wer

127 Using a double-blind, placebo-controlled, randomized crossover design, nontrea

128 Part 1 was a double-blind, randomized, placebo-controlled, single ascending dose study consisti

129 A randomized, double-blind, placebo-controlled, two-way crossover study was conducte

130 of 45 (80.0%) vaccinees and 4 of 21 (19.0%) placebo controls developed antibodies to PfCSP (P < .001

131 Use of placebo controls is justified in randomised controlled t

132 anastrozole (1 mg per day, oral) or matching placebo daily for 5 years.

133 AK002 and in 5% of the patients who received placebo (difference, 58 percentage points; 95% CI, 36 to

134 CD group had overall survival benefit versus placebo drug (hazard ratio [HR]: 0.87; 95% confidence in

135 Compared with patients switching from placebo, earlier and continuous ocrelizumab treatment pr

136 progression was noted among patients in the placebo-edaravone arm than among those in the edaravone-

137 The placebo effect suppresses the probability that an indivi

138 he u-opioid system-extensively implicated in placebo effects, a clinical phenomenon thought to rely o

139 ized to NSI-189 40 mg daily, 80 mg daily, or placebo for 12 weeks.

140 d patients to either high-dose eplerenone or placebo for 26 weeks.

141 26 weeks followed by nilotinib 300 mg versus placebo for another 26 weeks.

142 0 to 1.25 mg per kilogram of body weight) or placebo for at least 48 weeks.

143 (no data) and paliperidone outperformed the placebo for RR-any.

144 ium, olanzapine, and quetiapine outperformed placebo for RR-dep.

145 sensitivity in the FMT group compared to the placebo group (+5% +/- 12% in FMT group versus -3% +/- 3

146 cations in the pimodivir group (7.9%) versus placebo group (15.6%).

147 ) was similar in the LY-CoV555 group and the placebo group (19% and 14%, respectively; odds ratio, 1.

148 group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage

149 in the DHA group vs 10.2% of infants in the placebo group (absolute difference, -3.9% [95% CI, -6.8%

150 in the tranexamic acid groups vs 62% in the placebo group (difference, 3.5%; [90% 1-sided confidence

151 tuzumab group and 40.8 months (36-48) in the placebo group (hazard ratio 0.69, 95% CI 0.58-0.82); 8-y

152 clitaxel [n=1]) and one (<1%) patient in the placebo group (hepatic failure).

153 cine group and in 264 patients (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events per 100 per

154 ted vaccine (n=17), vaccine alone (n=16), or placebo group (n=16).

155 etween each of the two S44819 groups and the placebo group (OR 0.91 [95% CI 0.64-1.31]; p=0.80 for 15

156 -6.6) minutes per hour among patients in the placebo group (P = .29), with an estimated median differ

157 2 dose group and 20% (95% CI, 14-26) for the placebo group (P=0.016).

158 carboxymaltose group and 294 occurred in the placebo group (RR 0.74; 95% CI 0.58-0.94, p=0.013).

159 ients [12%]) versus 14 patients (30%) in the placebo group (with 6 infectious serious adverse events

160 69), 26.1% (18/69), and 27.5% (19/69) in the placebo group and 0%, 0%, 0%, 0%, 0%, and 1.4% (1/72) in

161 hildren underwent randomization (1999 in the placebo group and 2003 in the amoxicillin group).

162 f patients in each group had AEs (42% in the placebo group and 32% in the nabilone group).

163 o) in serum vitamin D3 was -0.1 ng/mL in the placebo group and 6.8 ng/mL in the 2000 IU/d group (abso

164 orter in the steroid group compared with the placebo group even though both groups included patients

165 n the vitamin D3 group and 33 (34.4%) in the placebo group had 1 or more severe exacerbations.

166 nce between the erythropoietin group and the placebo group in the incidence of death or severe neurod

167 nt between the zoledronic acid group and the placebo group over 24 months (-878 mm3 vs -919 mm3; betw

168 ariables in the 98 pomegranate juice and 102 placebo group subjects who completed the study did not d

169 ntration between the tofersen groups and the placebo group was 2 percentage points (95% confidence in

170 zumab group and 21.2% of the patients in the placebo group were still receiving supplemental oxygen.

171 tter in the melatonin group than that in the placebo group with a mean (SD) of 69.7 (21.2) and 60.7 (

172 08 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 mon

173 n-to-treat population, and 397 (102 [94%] in placebo group, 102 [94%] in 100 mg group, 98 [89%] in 20

174 Of these patients, 434 (106 [98%] in placebo group, 108 [100%] in 100 mg group, 109 [99%] in

175 60 (57%) of 104 patients in the placebo group, 63 (66%) of 96 in the ixekizumab Q4W grou

176 isiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE

177 ncrease of 8.2% (95% CI, 4.3 to 12.2) in the placebo group, for a between-group difference of -47.9 p

178 % +/- 12% in FMT group versus -3% +/- 32% in placebo group, mean difference 9%, 95% CI -5% to 28%, p

179 12% in the placebo group, p&0.05).

180 supplementation group and 4.0 +/- 2.2 in the placebo group, showing no group difference (p = 0.819).

181 gned to the intervention group and 52 to the placebo group.

182 e azithromycin group and 90.4% (10.1) in the placebo group.

183 olumab group and 6.4 months (3.3-9.6) in the placebo group.

184 the ticagrelor group and 223 patients in the placebo group.

185 ants in the active and 51.7% (76/147) in the placebo group.

186 the pertuzumab group and 23% (19-28) in the placebo group.

187 mg group, and 44 (57%) of 77 patients in the placebo group.

188 group, and three (4%) of 77 patients in the placebo group.

189 compared with 23 of 31 patients (74%) in the placebo group.

190 ere responders, compared to zero of 6 in the placebo group.

191 igned to the SEP-363856 group and 125 to the placebo group.

192 One patient died by sudden death in the placebo group.

193 ants receiving canakinumab compared with the placebo group.

194 roxaban group, and 3278 were assigned to the placebo group.

195 atients in the 300 IR group and 14.9% in the placebo group.

196 ed in the pertuzumab group compared with the placebo group.

197 in the zoledronic acid group vs -16.8 in the placebo group; between-group difference, 5.2 [95% CI, -2

198 he 10-mg/d vericiguat group, and 3.4% in the placebo group; those with syncope were 1.5%, 0.8%, and 0

199 ly differ between the hydroxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7];

200 died 53 newly diagnosed subjects enrolled in placebo groups of TrialNet clinical trials.

201 .47) and between the 10-mg/d vericiguat and placebo groups was -0.5 (95% CI, -4.6 to 3.5; P = .80).

202 in scores between the 15-mg/d vericiguat and placebo groups was -1.5 (95% CI, -5.5 to 2.5; P = .47) a

203 15-mg/d vericiguat, 10-mg/d vericiguat, and placebo groups were 295.0 m and 311.8m , 292.1 m and 318

204 More patients on lacosamide than placebo had >=50% (68.1%/46.3%) or >=75% (57.1%/36.4%) r

205 ays and 27.46% drinking days, while those on placebo had 35.58% heavy drinking days and 58.47% drinki

206 CI, 0 to 18.05), and residents randomized to placebo had a mean of 12.0 days (95% CI, 0 to 16.95) (ab

207 ears was 2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P = 0

208 evels) trial, atorvastatin was compared with placebo in 4,731 participants with recent stroke or tran

209 er 4 weeks' treatment with empagliflozin and placebo in a randomized, double-blind, placebo-controlle

210 y assigned to receive either vortioxetine or placebo in addition to cognitive training for 26 weeks.

211 bcutaneous administration of vosoritide with placebo in children with achondroplasia.

212 sk at baseline, and after methylphenidate or placebo in counter-balanced order.

213 Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute C

214 rametinib reduced the risk of relapse versus placebo in patients with resected, BRAF(V600)-mutant, st

215 e was noted between any active treatment and placebo in PBVC (amiloride vs placebo, 0.0% [95% CI -0.4

216 monthly subcutaneous evolocumab 420 mg with placebo in PLHIV with hypercholesterolemia/mixed dyslipi

217 Galcanezumab was superior to placebo in the preventive treatment of migraine and was

218 rted superior efficacy of fostemsavir versus placebo in the randomised cohort of the BRIGHTE study af

219 n metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabin

220 y prescribed, but their efficacy relative to placebo is modest, in part because the clinical diagnosi

221 (ixekizumab Q4W: 34 [35%] of 96, p=0.0094 vs placebo; ixekizumab Q2W: 41 [40%] of 102, p=0.0016; plac

222 nd after taking either donepezil (5 mg) or a placebo (lactose) pill.

223 topical GM-CSF (M+GM) versus miltefosine and placebo (M+P) versus standard Sb v in the treatment of 1

224 al enrolled 252 participants (210 vaccine/42 placebo; median age 23 years; 43% female) between 9 Febr

225 trimoxazole twice daily (n = 170) or matched placebo (n = 172) for between 12 and 42 months.

226 injections 28 days apart (20 ug, n = 201) or placebo (n = 199) and were followed up for 72 weeks.

227 e either 150 mg/d of resveratrol (n = 20) or placebo (n = 21) for 6 mo.

228 epletion (N = 24), DA depletion (N = 24), or placebo (N = 22) group.

229 200 mg twice daily for 8 doses) (n = 242) or placebo (n = 237).

230 4457845, 4 mg orally, once daily; n = 16) or placebo (n = 29) for 10 days.

231 ive 100/25 mg L-dopa/benserazide (n = 32) or placebo (n = 31) prior to each of twenty cognitive train

232 izumab at a flat dose of 200 mg (n = 514) or placebo (n = 505) every 3 weeks for 1 year or until dise

233 ek intranasal oxytocin (48IU/day, n = 53) or placebo (n = 53) group.

234 Patients received JNJ-8678 (n = 37) or placebo (n = 7).

235 37 patients were randomly assigned to either placebo (n=108) or cenobamate 100 mg (n=108), 200 mg (n=

236 vel OPV2-c1 (n=17), novel OPV2-c2 (n=16), or placebo (n=17).

237 body wt per day; n=52) NaHCO(3) or matching placebo (n=52).

238 nce weekly for 15 weeks [n = 30], or matched placebo [n = 30]).

239 Relative to placebo, nicotine induced more NAcc reactivity to reward

240 ntervention in stage 2, while sertraline and placebo nonresponders crossed over to bupropion and sert

241 [15-30]), with percentage differences versus placebo of 37% (95% CI 26-48) for the every 4 weeks grou

242 2-dose EBOV GP with adjuvant, compared with placebo on Day 35, which persisted through 1 year.

243 ent doses of a novel D1 agonist (relative to placebo) on reactivity to reward-predicting cues (Pavlov

244 months) were randomized to oral JNJ-8678 or placebo once daily for 7 days.

245 second trimester to blinded weekly doses of placebo or 4,200, 16,800, or 28,000 IU of vitamin D3 thr

246 se of PCV20 followed 1 month later by saline placebo or a single dose of PCV13 followed 1 month later

247 Eight RCTs of DAA therapy vs placebo or an outdated antiviral regimen, 48 other treat

248 s, they received an expectancy manipulation (placebo or no-treatment) delivered by VEx or text-only c

249 were assigned to alteplase and 414 (49%) to placebo or standard care.

250 as 1369 patients in the control arm received placebo or standard care.

251 with either capivasertib 400 mg or matching placebo, orally twice daily on an intermittent weekly sc

252 nts given aldafermin vs 9% of patients given placebo (P = .20).

253 ients treated with LS + inulin compared with placebo (P = 0.029).

254 e to the first exacerbation as compared with placebo (P = 0.03 for 10-mg brensocatib vs. placebo; P =

255 o 0.98) in the 10-mg group, as compared with placebo (P = 0.04), and 0.75 (95% CI, 0.50 to 1.13) in t

256 o 1.13) in the 25-mg group, as compared with placebo (P = 0.17).

257 e modified the effects of L-thyroxine versus placebo (P for interaction = 0.20 and 0.82, respectively

258 ended to mildly increase (3% bezafibrate, 5% placebo, P = .14).

259 135 and PP was 54.3% reltecimod versus 40.3% placebo, P = 0.021.

260 nt success was 48.6% reltecimod versus 39.9% placebo, P = 0.135 and PP was 54.3% reltecimod versus 40

261 placebo (P = 0.03 for 10-mg brensocatib vs. placebo; P = 0.04 for 25-mg brensocatib vs. placebo).

262 MA group had one open-label MDMA session and placebo participants crossed over to receive three open-

263 was recorded in 37 (2%) TAK-003 and 13 (7%) placebo participants, with a relative risk of 0.35 (0.19

264 ons daily for 5 wk: low-nitrate vegetables + placebo pills, low-nitrate vegetables + nitrate pills (3

265 green vegetables containing 300 mg nitrate + placebo pills.

266 ulted in longer median overall survival than placebo plus androgen-deprivation therapy among men with

267 rapy group and 19.8 months (8.1-24.5) in the placebo plus chemotherapy group.

268 1.0 point [95% CI -1.3 to 3.2] increase) and placebo plus pemetrexed-platinum (-2.6 points [-5.8 to 0

269 p A), atezolizumab monotherapy (group B), or placebo plus platinum-based chemotherapy (group C).

270 ble-blind, placebo-controlled trial (vaccine-placebo ratio, 2:1) at 106 plaque-forming units (PFU) in

271 who were randomized, 17 dipyridamole and 18 placebo recipients had baseline and week 12 data availab

272 pe were significantly higher in Triplex than placebo recipients.

273 et led to lower 90-day mortality than use of placebo (relative risk, 0.19; 95% CI, 0.05 to 0.75), whe

274 However, whether non-deceptive placebos represent genuine psychobiological effects is u

275 15 versus 519 patients; empagliflozin versus placebo, respectively; hazard ratio [HR], 0.76; 95% CI,

276 es participants about factors known to cause placebo response, which was administered prior to the pr

277 Dupilumab (vs placebo) resulted in significantly greater improvement i

278 olizumab versus 18.0 months (13.6-20.1) with placebo (stratified HR 0.71, 0.54-0.94]).

279 ned 1:1 to empagliflozin 10 mg once daily or placebo, stratified by age (<65 and >=65 years) and glyc

280 g for vemurafenib was achieved by means of a placebo tablet.

281 ban than vitamin K antagonist (VKA) and with placebo than aspirin.

282 hat, with respect to the administration of a placebo, the local delivery of a clinically deployable f

283 or high-quality evidence that, compared with placebo, the single-species product B animalis subsp lac

284 ed to receive luspatercept and 76 to receive placebo; the baseline characteristics of the patients we

285 icantly increased from 12% in patients given placebo to 17% in those given dexmedetomidine: 1.48 (97.

286 e effects of administering omalizumab versus placebo to asthmatics in a randomized, double-blind plac

287 From placebo to fentanyl, leg VO2 , QL and O(2) delivery were

288 erative intravenous iron was not superior to placebo to reduce need for blood transfusion when admini

289 emsavir (at a dose of 600 mg twice daily) or placebo to their failing regimen for 8 days, followed by

290 ary composite end point occurred in 24.7% of placebo-treated patients versus 18.2% of icosapent ethyl

291 sus four (<1%) of 2218 patients treated with placebo; treatment-emergent hypocalcaemia occurred in 15

292 ficant interaction (P <= 0.05) to ICS versus placebo treatments.

293 S44819 twice a day, and 193 (33%) to receive placebo twice a day.

294 bility was 53.3% (95% CI, 0.36 to 0.68) with placebo versus 85.0% (95% CI, 0.70 to 0.93) with sorafen

295 carboxymaltose in 100 mL normal saline, and placebo was 100 mL normal saline, both given as an infus

296 0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a

297 Nilotinib 150 mg versus matching placebo was taken orally once daily for 26 weeks followe

298 nt formulations support equivalent safety to placebo with less toxicity than oral iron.

299 l without relapse or distant metastasis than placebo with no apparent long-term toxic effects.

300 nificant improvements in ACR50 compared with placebo, with an acceptable safety profile.